Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Feugier

Showing results (131-140 of 164) with videos related to

Pageof 17
Sort By:
Blood|November 19, 2020
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSASteven Le Gouill, Hervé Ghesquières, Lucie Oberic, et al.
The Lancet. Oncology|January 20, 2019
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 studyRené-Olivier Casasnovas, Reda Bouabdallah, Pauline Brice, et al.
The Lancet. Oncology|February 25, 2018
A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohortsSarah Huet, Bruno Tesson, Jean-Philippe Jais, et al.
Leukemia|September 16, 2020
Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemiaRémi Letestu, Abdelmalek Dahmani, Marouane Boubaya, et al.
Nature Medicine|May 14, 2024
Author Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trialRoch Houot, Emmanuel Bachy, Guillaume Cartron, et al.
Nature Medicine|September 14, 2023
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trialRoch Houot, Emmanuel Bachy, Guillaume Cartron, et al.
Blood|June 11, 2025
Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatmentAlexis Claudel, Anne-Ségolène Cottereau, Emmanuel Bachy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2019
Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA StudyEmmanuel Bachy, John F Seymour, Pierre Feugier, et al.
Leukemia|April 27, 2024
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma networkLuca Fischer, Linmiao Jiang, Jan Dürig, et al.
The Lancet. Haematology|July 21, 2019
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trialAnne-Sophie Michallet, Marie-Sarah Dilhuydy, Fabien Subtil, et al.
Pageof 17

Showing results (131-140 of 164) with videos related to

Sort By:
Pageof 17
Blood|November 19, 2020
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSASteven Le Gouill, Hervé Ghesquières, Lucie Oberic, et al.
The Lancet. Oncology|January 20, 2019
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 studyRené-Olivier Casasnovas, Reda Bouabdallah, Pauline Brice, et al.
The Lancet. Oncology|February 25, 2018
A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohortsSarah Huet, Bruno Tesson, Jean-Philippe Jais, et al.
Leukemia|September 16, 2020
Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemiaRémi Letestu, Abdelmalek Dahmani, Marouane Boubaya, et al.
Nature Medicine|May 14, 2024
Author Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trialRoch Houot, Emmanuel Bachy, Guillaume Cartron, et al.
Nature Medicine|September 14, 2023
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trialRoch Houot, Emmanuel Bachy, Guillaume Cartron, et al.
Blood|June 11, 2025
Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatmentAlexis Claudel, Anne-Ségolène Cottereau, Emmanuel Bachy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2019
Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA StudyEmmanuel Bachy, John F Seymour, Pierre Feugier, et al.
Leukemia|April 27, 2024
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma networkLuca Fischer, Linmiao Jiang, Jan Dürig, et al.
The Lancet. Haematology|July 21, 2019
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trialAnne-Sophie Michallet, Marie-Sarah Dilhuydy, Fabien Subtil, et al.
Pageof 17